Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:47:28.204Z.
Calculation as of: 2026-10-06T15:47:28.204Z.
Quote observation: 2026-10-06T15:44:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$510.83M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$540.09M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$541.82M
EV/EBIT Ratio
N/A
TTM Avg
189.50x
3Y Avg
189.50x
5Y Avg
189.50x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $522.07M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $523.14M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $523.17M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $515.72M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $510.83M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $540.09M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $539.42M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $541.37M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $541.82M | N/A | 189.50x | 189.50x | 189.50x |
| Oculis Holding AG (OCS)vs › | $501.67M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
